의학물리학

본문글자크기
  • [Int J Radiat Oncol Biol Phys .] Development and Validation of a Normal Tissue Complication Probability Model for Lymphedema After Radiation Therapy in Breast Cancer

    [Int J Radiat Oncol Biol Phys .] Development and Validation of a Normal Tissue Complication Probability Model for Lymphedema After Radiation Therapy in Breast Cancer

    이화의대, 연세의대 / 박예인, 김규보*, 홍채선*

  • 출처
    Int J Radiat Oncol Biol Phys .
  • 등재일
    2023 Feb 4
  • 저널이슈번호
    S0360-3016(23)00106-2.
  • 내용

    바로가기  >

    Abstract
    Purpose: To develop and test a multivariable normal tissue complication probability (NTCP) model predicting lymphedema in patients with breast cancer receiving radiation therapy.

    Methods and materials: We retrospectively reviewed 1345 patients with breast cancer who received radiation therapy from 2 independent institutions. The patients were divided into a training cohort (institution A, n = 368, all treated with 3-dimensional conformal external beam radiation therapy [RT] with 2 Gy/fraction) and an external validation cohort (institution B, n = 977, treated either with 3-dimensional conformal external beam RT or with volumetric modulated RT and either with 1.8-2.0 Gy/fraction or with 2.67 Gy/fraction). Axillary-lateral thoracic vessel juncture (ALTJ) was delineated. The multivariable model was generated using dosimetric and clinical parameters. The performance of the model was comprehensively validated internally and externally.

    Results: During a median follow-up of 78.7 months for the entire cohort, 97 patients (7.2%) developed lymphedema. The multivariable model that took into account the number of lymph nodes dissected, as well as the volume of the ALTJ receiving a dose ≥35 Gy equivalent doses in 2-Gy fractions (ALTJ V35), showed good agreement between predicted and observed results for both internal and external validation (Hosmer-Lemeshow P value > .05). The area under the receiver operating characteristic curve (AUC) and negative log-likelihood values for the multivariable NTCP model were 0.89 and 0.19 in internal validation and 0.83 and 0.19 in external validation. In addition, the multivariable model performance was acceptable for hypofractionated regimens (AUC 0.70) and volumetric modulated arc therapy (AUC 0.69). The number of lymph nodes dissected and ALTJ V35 were found to be the most important factors influencing lymphedema after radiation therapy.

    Conclusions: We first developed and validated the multivariable NTCP model for the lymphedema incidence in patients with breast cancer after radiation therapy. The multivariable NTCP model showed excellent performance and robustness in predicting lymphedema in both internal and completely independent external validations. The multivariable model for lymphedema prediction was robust and reliable for different treatment modalities and fractionation regimens.

     

     

    Affiliations

    Ye-In Park 1, Jee Suk Chang 1, Heejoo Ko 2, Sang Hee Im 3, Jin Sung Kim 1, Hwa Kyung Byun 1, Yong Bae Kim 1, Wonguen Jung 4, Kyubo Kim 5, Chae-Seon Hong 6
    1Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.
    2College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
    3Department of Rehabilitation Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
    4Department of Radiation Oncology, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
    5Department of Radiation Oncology, Ewha Womans University College of Medicine, Seoul, Republic of Korea. Electronic address: kyubokim.ro@gmail.com.
    6Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: cs.hong@yuhs.ac.

  • 편집위원

    이 연구는 방사선치료를 받은 유방암 환자의 림프부종 위험을 예측하기 위해 정상조직손상확률(NTCP) 모델을 최초로 개발하고 검증했습니다. 임상 및 선량인자를 결합한 다변수 NTCP 모델은 내부 검증과 완전히 독립적인 외부 검증 모두에서 림프부종을 예측하는 데 탁월한 성능과 견고성을 보여주었습니다. 림프부종 예측을 위한 다변량 모델은 다양한 치료 양식 및 분류 요법에 대해 견고하고 신뢰할 수 있었습니다. 이 연구는 임상에서 림프부종을 예측하고 발병을 예방하기 위한 임상지침을 안내할 수 있습니다.

    2023-04-05 10:47:54

  • 덧글달기
    덧글달기
       IP : 3.138.33.178

    등록